P
Philip S. Boonstra
Researcher at University of Michigan
Publications - 73
Citations - 1731
Philip S. Boonstra is an academic researcher from University of Michigan. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 13, co-authored 63 publications receiving 835 citations. Previous affiliations of Philip S. Boonstra include Molecular and Behavioral Neuroscience Institute.
Papers
More filters
Journal ArticleDOI
Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry.
Ryan P. Barbaro,Graeme MacLaren,Philip S. Boonstra,Theodore J. Iwashyna,Arthur S. Slutsky,Eddy Fan,Robert H. Bartlett,Joseph E. Tonna,Robert Hyslop,Jeffrey J Fanning,Peter Rycus,Steve J Hyer,Marc Anders,Cara Agerstrand,K. Hryniewicz,Rodrigo Diaz,Roberto Lorusso,Alain Combes,Daniel Brodie +18 more
TL;DR: In patients with COVID-19 who received ECMO, both estimated mortality 90 days after ECMO and mortality in those with a final disposition of death or hospital discharge were less than 40%.
Journal ArticleDOI
Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry.
Ryan P. Barbaro,Graeme MacLaren,Philip S. Boonstra,Alain Combes,Cara Agerstrand,Gail M. Annich,Rodrigo Diaz,Eddy Fan,K. Hryniewicz,Roberto Lorusso,Matthew L. Paden,Christine M. Stead,Justyna Swol,Theodore J. Iwashyna,Arthur S. Slutsky,Daniel Brodie +15 more
TL;DR: In this paper, the authors examined patient selection, treatments, outcomes, and ECMO center characteristics over the course of the COVID-19 pandemic to date, and concluded that the role of extracorporeal membrane oxygenation (ECMO) has changed and the use of ECMO has increased.
Journal ArticleDOI
Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.
Asra Ahmed,Samuel A. Merrill,Fares Alsawah,Paula L. Bockenstedt,Erica L. Campagnaro,Sumana Devata,Scott D. Gitlin,Mark S. Kaminski,Alice M. Cusick,Tycel Phillips,Suman L. Sood,Moshe Talpaz,Albert Thomas Quiery,Philip S. Boonstra,Ryan A. Wilcox +14 more
TL;DR: Preliminary data suggest that ruxolitinib is active, well tolerated, and manageable in the outpatient setting in patients with secondary haemophagocytic lymphohistiocytosis and other cytokine-release syndromes and warrant further investigation.
Journal ArticleDOI
Efficacy of Staged Excision With Permanent Section Margin Control for Cutaneous Head and Neck Melanoma
Jeffrey S. Moyer,Shannon F. Rudy,Philip S. Boonstra,Casey T. Kraft,Steven B. Chinn,Shan R. Baker,Jennifer L. Schwartz,Christopher K. Bichakjian,Douglas R. Fullen,Alison B. Durham,Lori Lowe,Timothy M. Johnson +11 more
TL;DR: Staged excision with comprehensive permanent section margin control of melanomas arising in chronically sun-damaged skin on the head and neck has favorable recurrence rates when melanoma margins are difficult to assess, and recurrence Rates are high with traditional techniques.
Journal ArticleDOI
Development and validation of the pediatric risk estimate score for children using extracorporeal respiratory support (Ped-RESCUERS)
Ryan P. Barbaro,Philip S. Boonstra,Matthew L. Paden,L. Roberts,Gail M. Annich,Robert H. Bartlett,Frank W. Moler,Matthew M. Davis +7 more
TL;DR: Ped-RESCUERS provides a novel measure of pre-ECMO mortality risk and should seek external validation and improved discrimination of this mortality prediction tool.